Novo Nordisk raised its full-year outlook on 4 November after continued demand for its GLP-1 medicines, including Wegovy. Third-quarter adjusted operating profit rose 27% at constant exchange rates, while reported operating profit fell 9% on the same currency basis.
The difference reflects exceptional costs and the comparison with last year. The company now expects adjusted sales and adjusted operating profit growth in a range of minus 2% to plus 2% at constant exchange rates for 2026. The improved outlook is linked to higher expectations for GLP-1 sales, including the obesity portfolio.
Growth needs a second reading
The headline increase is an adjusted measure. It should not be presented as a 27% rise in the reported operating result. Adjustments can help compare underlying trading across periods, but they do not make the costs recorded in the accounts disappear.
That distinction matters when a business is expanding products and manufacturing capacity at the same time. Investors need to consider demand, spending and the quality of earnings together. A stronger quarter can improve expectations without removing execution risks or guaranteeing the next year's performance.
The outlook is not the result
The full-year range is a management forecast. It is not a completed annual result, and constant-currency growth differs from growth measured directly in Danish kroner. Comparing figures on different bases can exaggerate either improvement or deterioration.
For readers following the weight-management market, the immediate development is the upgrade to Novo's expectations, rather than a new medical recommendation. Commercial momentum does not establish which treatment is suitable for an individual patient. For the business, the next test is turning product demand into sustained sales and earnings while managing the costs that complicate this quarter's profit picture.
